Selinexor
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 661 publications
Incorporation of selinexor into conditioning regimens prior to allogeneic hematopoietic stem cell transplantation: a single-center clinical study.
Journal: Hematology (Amsterdam, Netherlands)
Published: August 27, 2026
Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study.
Journal: Annals of medicine
Published: August 03, 2026
Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 30, 2026
Phase I dose escalation of the Exportin 1 inhibitor, Selinexor, in combination with chemoradiation in patients with newly diagnosed glioblastoma.
Journal: medRxiv : the preprint server for health sciences
Published: July 17, 2026
Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft.
Journal: Neoplasia (New York, N.Y.)
Published: July 10, 2026
Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma.
Journal: British journal of haematology
Published: June 23, 2026
Selinexor for myelofibrosis or a drug in search of a disease?
Journal: Blood cancer journal
Published: June 22, 2026
Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: June 10, 2026
Six Years Since Selinexor Approval for Relapsed Multiple Myeloma: What Have We Learned?
Journal: Cancer investigation
Published: June 05, 2026
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 02, 2026
Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition.
Journal: Seminars in hematology
Published: May 11, 2026
Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways.
Journal: British journal of haematology
Published: May 06, 2026
Last Updated: 09/26/2026